MC-Val-Cit-PAB-MMAF is an antibody-drug conjugate (ADC) component that exhibits antitumor properties through the action of the tubulin inhibitor, monomethyl auristatin F (MMAF), which is connected by a cathepsin-cleavable linker, MC-Val-Cit-PAB.

NAMPT inhibitor-linker 2, a drug-linker conjugate for antibody-drug conjugates (ADCs), comprises an NAMPT inhibitor payload and a linker. When combined with an anti-c-Kit monoclonal antibody to form ADC-4, it demonstrates potent efficacy against c-Kit expressing cell lines, including GIST-T1 and NCI-H526, with IC50 values of <7 pM and 40 pM, respectively.

Mal-PEG4-VA-PBD is a drug-linker conjugate for Antibody-Drug Conjugates (ADCs), comprising the antitumor antibiotic Pyrrolobenzodiazepine (PBD), connected through Mal-PEG4-VA.

MC-Gly-Gly-Phe-Gly-(R)-Cyclopropane-Exatecan 是抗体偶联活性分子的一部分 (drug-linker conjugate for ADC)，包含 Exatecan 。Exatecan 是一种 DNA 拓扑异构酶 I (Topoisomerase I) 抑制剂 (IC50=2.2 μM)。

PAC is a chemical conjugate consisting of an ADCs linker and PROTACs linked to an antibody. When PAC is conjugated to an antibody, it exhibits enhanced degradation of estrogen receptor-alpha (ERα) in comparison to PROTAC alone.

Comp Ie (MC-(β-Ala)-PABC-(β-D-GlcUA)-amide-PEG1-CH2-CC-885) 为一种新型抗体新降解剂偶联活性分子 (AnDC) 的合成降解剂偶联物。